Advertisement

AACR 2023: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable NSCLC
Posted: 05/08/2023 | By: Sarah Campen, PharmD

The phase III AEGEAN trial is a randomized, double-blind, placebo-controlled trial assessing the efficacy of neoadjuvant durvalumab plus chemotherapy followed by surgery and adjuvant durvalumab in patients with resectable non–small cell lung cancer (NSCLC). Results from the trial were presented by Heymach et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract CT005).

Question 1 of 5

What patient population was included in the AEGEAN study?

Choose 1